Unlock Exclusive Discounts & Flash Sales! Click Here to Join the Deals on Every Wednesday!
Breast cancer is one of the most common cancer in the world. Abemaciclib (ABE), ribociclib (RIB), and palbociclib (PAL) are CDK4/6 inhibitors that work by targeting overactive CDK4/6 in cancer cells and stopping their cell cycle, thereby slowing proliferation. Advances in the treatment of HR+/HER2- breast cancer phenotype have been made with the introduction of abemaciclib, ribociclib, and palbociclib, inhibitors of cyclin D dependent kinases 4 and 6 (CDK4/6). This service provides a novel, fast, cheap, and green CE method for the simultaneous determination of these three CDK4/6 inhibitors in less than 4 min.